Cash & Leverage
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
Formula
(Market Cap + Net Debt) / EBITDAEV/EBITDA History
Historically priceyAbove avgAround avgBelow avgHistorically cheap
No data available
How to read this chart
Unlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
Key caveats
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is TGTX EV/EBITDA High or Low Right Now?
TG Therapeutics, Inc.'s EV/EBITDA is currently 58.8, which is above average relative to its 10-year historical range. The 10-year median EV/EBITDA for TGTX is approximately 52.7. See all TGTX valuation metrics →
Pro — up to 30-year history
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.